E-Greetings from the Allergy Advocacy Association

December 2020

Winter is here and 2020 is finally drawing to a close. As we make our plans and set our goals for the New Year, we would love to hear your thoughts on how we're doing, as well as your suggestions for services we can provide to help keep everyone safe. Feel free to drop us a note at This email address is being protected from spambots. You need JavaScript enabled to view it. or post something on our Facebook page at: https://www.facebook.com/allergy.advocacy.37/

Looking for a worthy cause to make a donation to? We humbly suggest our "Remembering Ruthie" fundraising campaign. Please use our Website to register as a new member of our association. We need your help to save lives from diagnosed and undiagnosed life threatening allergies thru our Epi Near You New York anaphylaxis emergency training program. Here is the link leading you to our donations page. We are very grateful for any support you may choose to offer us.

ANNOUNCING: Anaphylaxis Emergency Training direct from the internet into your home or office!

Our Epi Near You NY anaphylaxis emergency training program is now VIRTUAL! We will broadcast our next seminar via our website on THURSDAY, JANUARY 14th, 2021 at 12noon.

Our association would help provide:

  • Free state approved training presentation
  • New York State recognized certification
  • Assistance for public entities to obtain a non-patient specific prescription for emergency epinephrine

We hope you will find New Year's e-news issue interesting and informative. Stay safe and healthy! Best wishes to one and all in 2021!

Overflowing thanksgiving; glorious gratitude!

As we wind up yet another year, it’s a good time to sit back and reflect on what has been accomplished in 2020. Of course nothing would have been possible without the hard work and support we receive every day from so many in our community. Here’s our founder Jon Terry’s list of people and organizations that have been especially helpful this past year in reaching our ongoing vision of "Not another life lost to anaphylaxis - not another life lost ANY life-threatening allergies!"

“Overflowing thanksgiving; glorious gratitude!”*

Allergy Advocacy Association staff in zoom call

By Jon Terry
December 17th, 2020

Greetings. At this time of an international health crisis, when all of us are confronting so many challenges and difficulties, I sincerely hope you and your families are safe and healthy.

Usually, my end of year letter is focused upon gratitude and thanksgiving, a list of items I felt fortunate to have participated in or achieved thru our program of awareness alertness and action.

Continue Reading

US Senate Passes FASTER Act, Brings Mandatory Sesame Labeling One Step Closer

Concerning successful advocacy during 2020 in Washington DC, congratulations to everyone who helped pass the The Food Allergy Safety, Treatment, Education, and Research (FASTER) Act of 2020 thru the United States Congress. Next step: The house and the senate will meet to reconcile their bills. After that the bill heads for the White House for the President's signature and enactment of the legislation. Everybody please keep your prayers and positive thoughts focused upon Capitol Hill.

US Senate Passes FASTER Act, Brings Mandatory Sesame Labeling One Step Closer

FARE Activists in front of U.S. Capitol Mar 2020

S 3451 will add sesame as the ninth major allergen and prioritize food allergy research; bill now heads to the House for consideration

By News Wire ~ 3rd Party Press Release
December 10th, 2020

Today, FARE (Food Allergy Research & Education), the world’s leading non-governmental organization engaged in food allergy advocacy and the largest private funder of food allergy research, announces the quick action and unanimous passage of The Food Allergy Safety, Treatment, Education, and Research (FASTER) Act of 2020, S. 3451 by the U.S. Senate. Since the bill’s Senate introduction on March 12, FARE has worked extremely closely with the Senate Committee on Health, Education, Labor, and Pensions (HELP) and the House Committee on Energy and Commerce, as well as co-sponsors Senators Tim Scott (R-SC) and Chris Murphy (D-CT) to move this legislation forward.

Continue Reading

Those Who Give the COVID-19 Vaccine Need to Be Trained to Use an EpiPen

Now that vaccines protecting people from the corona virus have arrived, the danger of dangerous attacks of anaphylaxis have arrived as well. Proper administration of epinephrine is now almost as important as using the vaccine itself. Our association fully supports comprehensive training on how to use an epinephrine auto-injector (EAI) device in an anaphylaxis emergency.

Those Who Give the COVID-19 Vaccine Need to Be Trained to Use an EpiPen

Nurse Receiving Covid-19 Vaccine Dec 2020
(AP Photo/Mark Lennihan, Pool) AP

By Robert K. Houton

The COVID-19 vaccination that began rolling out this week to frontline medical workers will hopefully end our long nightmare with this virus and the pandemic. But there is one concern: 1.6% of the American population, or roughly 5 million people, have experienced a severe allergic attack, called anaphylaxis, and may have a severe reaction to the vaccine.

As a result, all sites that are injecting the Pfizer-BioNTech COVID-19 vaccine are required to have epinephrine auto-injector devices (Epi-Pens) as a safety precaution if an allergic reaction, occurs after the vaccine is given. Epinephrine, also known as adrenaline, is the only medication recommended as a first-treatment medicine in reversing the life-threatening reaction in an anaphylactic attack.

Continue Reading

ACAAI Releases Guidance on Risk of Allergic Reactions to the Pfizer-BioNTech COVID-19 Vaccine

ACAAI: Allergic reactions to vaccines rarely occur

Regarding vaccines for immunization against COVID-19, many people have concerns about how safe they are. Are there significant risks of allergic reaction from vaccination? Are adequate procedures being followed? This article provides guidance and recommendations from the American College of Allergy, Asthma and Immunology (ACAAI) an association of allergists-immunologists and allied health professionals.

Covid-19 Vaccination In Arm, Dec. 2020

American College of Allergy, Asthma, and Immunology Releases Guidance on Risk of Allergic Reactions to the Pfizer-BioNTech COVID-19 Vaccine

December 14th, 2020

With the emergency use authorization of the Pfizer-BioNTech COVID-19 vaccine by the FDA on December 11, 2020, and distribution beginning today, the American College of Allergy, Asthma and Immunology COVID-19 Vaccine Task Force recommends the following guidance related to risk of an allergic reaction on vaccination for those who receive the vaccine. These recommendations are based on best knowledge to date but could change at any time, pending new information and further guidance from the FDA or CDC.

Continue Reading